Calcitonin oral - Biocon/Seachaid Pharmaceuticals
Alternative Names: CT 025; NCT-025; OratoninLatest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator Biocon
- Developer Seachaid Pharmaceuticals
- Class Antihypercalcaemics; Calcium regulators; Neuropeptides; Osteoporosis therapies; Peptide hormones
- Mechanism of Action Calcitonin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 28 May 2019 No recent reports of development identified for phase-I development in Postmenopausal-osteoporosis in USA (PO)
- 02 Apr 2004 The Synerobex joint venture between Nobex Corporation and Elan Corporation has been dissolved; Oratonin™ is now owned solely by Nobex
- 24 Mar 2004 Oratonin™ is available for licensing worldwide (http://www.nobexcorp.com)